129139-48-6

Basic information

• Product Name: 5-methoxy-N1-methylbenzene-1,2-diamine
• Synonyms: 5-methoxy-N1-methylbenzene-1,2-diamine;4-methoxy-N2-methyl-1,2-Benzenediamine;4-Methoxy-N*2*-methyl-benzene-1,2-diamine
• CAS NO: 129139-48-6
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19368
• Mol File: 129139-48-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-methoxy-N1-methylbenzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methoxy-N1-methylbenzene-1,2-diamine(129139-48-6)
• EPA Substance Registry System: 5-methoxy-N1-methylbenzene-1,2-diamine(129139-48-6)

Safety Data

• Hazardous Substances Data: 129139-48-6(Hazardous Substances Data)

Upstream product

• 446-38-8 2-fluoro-4-methoxy-1-nitro-benzene 
• 20628-18-6 1-acetamido-5-methoxy-2nitrobenzene 
• 69397-93-9 N-methyl-5-methoxy-2-nitroaniline 

Downstream Products

• 185428-18-6 rivoglitazone 
• 4583-86-2 5-methoxy-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one 
• 10394-42-0 6-methoxy-1-methylbenzimidazole 
• 657430-21-2 6-methoxy-1-methylbenzimidazole-2-methanol 
• 945023-35-8 6-methoxy-1-methyl-1H-benzo[d]imidazol-2-amine 
• 28249-63-0 6-methoxy-1-methyl-2-(2-methyl-3,5-dinitro-phenyl)-2,3-dihydro-1H-benzo[1,3,2]diazaborole 

Relevant articles and documents

Benzimidazole compound and application thereof

The invention relates to a benzimidazole compound and an application thereof. The structure of the benzimidazole compound is shown as a formula I, and the compound is used as a focal adhesion kinase inhibitor and shows relatively good focal adhesion kinase (FAK) inhibition activity. Meanwhile, the benzimidazole compound has stronger medicine effect and better pharmacokinetic property and/or toxicological characteristics, such as good brain/plasma ratio, good bioavailability, good metabolic stability, and reduced inhibition to respiratory action of mitochondria. The benzimidazole compound has agood clinical application prospect.

Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym- may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

New betamimetics for the treatment of respiratory complaints

The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and R1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.